Invitrogen™ Rituximab Recombinant Human Monoclonal Antibody (10F381 (rituximab))

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA547773

Catalog No. PIMA547773

Description

Specificity: CD20 (Human B-lymphocyte-restricted differentiation antigen, Bp35), is a hydrophobic transmembrane protein with a molecular weight of approximately 35 kDa located on pre-B and mature B lymphocytes, and most B-cell non-Hodgkin's lymphomas, but is not found on stem cells, pro-B cells, normal plasma cells or other normal tissues.

Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with certain autoimmune diseases and types of cancer, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.

Specifications

• Antigen: Rituximab
• Classification: Recombinant Monoclonal
• Concentration: 1 mg/mL
• Formulation: PBS with 0.02% ProClin 300
• Gene Accession No.: P08101, P08508
• Host Species: Human
• Purification Method: Protein A
• Regulatory Status: RUO
• Gene ID (Entrez): 14130, 14131
• Content And Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
• Form: Liquid

• Applications: Flow Cytometry
• Clone: 10F381 (rituximab)
• Conjugate: Unconjugated
• Gene: Fcgr3
• Gene Alias: IDEC-C2B8; Rituxan
• Immunogen: Human lymphoblastoid cell line SB.
• Quantity: 200 μg
• Primary or Secondary: Primary
• Target Species: Human, Rhesus Macaque, Cynomolgus Monkey
• Product Type: Antibody
• Isotype: IgG1 κ